Pharming Group (NASDAQ:PHAR) Releases Earnings Results, Beats Estimates By $0.15 EPS

Pharming Group (NASDAQ:PHAR) released its earnings results on Tuesday. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15, FiscalAI reports. Pharming Group had a return on equity of 3.40% and a net margin of 2.51%. The firm had revenue of $117.60 million for the quarter, compared to analysts’ expectations of $117.60 million.

Pharming Group Price Performance

Shares of PHAR stock opened at $11.90 on Tuesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.01 and a quick ratio of 2.31. The company has a market capitalization of $842.28 million, a P/E ratio of 99.17 and a beta of -0.05. The company’s 50-day simple moving average is $10.69 and its two-hundred day simple moving average is $13.92. Pharming Group has a one year low of $9.11 and a one year high of $21.34.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Canaccord Genuity Group set a $38.00 price objective on Pharming Group in a report on Wednesday, September 23rd. Weiss Ratings reiterated a “sell (d)” rating on shares of Pharming Group in a research note on Friday, August 7th. Wall Street Zen upgraded Pharming Group to a “hold” rating in a research note on Saturday. Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a research report on Friday. Finally, Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a research note on Thursday, July 30th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $38.67.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.